Vaxart (OTCMKTS:VXRT – Get Free Report) is projected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $27.20 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:30 PM ET.
Vaxart (OTCMKTS:VXRT – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.06. The company had revenue of $27.18 million during the quarter, compared to analysts’ expectations of $26.21 million. Vaxart had a net margin of 15.88% and a return on equity of 53.04%. On average, analysts expect Vaxart to post ($0.68) EPS for the current fiscal year and ($1.03) EPS for the next fiscal year.
Vaxart Price Performance
Shares of VXRT stock traded up $0.01 during trading hours on Wednesday, reaching $0.41. The company had a trading volume of 27,495 shares, compared to its average volume of 474,087. The company has a 50 day moving average of $0.46 and a 200 day moving average of $0.58. The firm has a market cap of $99.80 million, a price-to-earnings ratio of 2.56 and a beta of 1.15. Vaxart has a 1-year low of $0.32 and a 1-year high of $0.84.
Wall Street Analyst Weigh In
Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a report on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, Vaxart has a consensus rating of “Hold”.
Read Our Latest Research Report on VXRT
About Vaxart
Vaxart, Inc is a biotechnology company focused on developing oral recombinant vaccines delivered in tablet form. Its proprietary platform is designed to stimulate immune responses at mucosal surfaces, such as those in the nose and mouth, in addition to generating systemic immunity. The company’s approach is intended to offer a needle-free alternative to traditional injectable vaccines.
Vaxart’s development programs have included oral vaccine candidates for coronavirus infections, norovirus and influenza.
Recommended Stories
- Five stocks we like better than Vaxart
- Advanced Micro Devices’ Q3 Results Answer a Big Question, But Another Remains
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
